COMPARATIVE ANALYSIS OF THE KINEMATICS AND KINETICS OF FORWARD AND BACKWARD HUMAN LOCOMOTION

Although common in occurrence one of the least studied modes of human motion is backward locomotion. Backward walking and jogging are currently being used as components of physical therapy for persons who have suffered trauma or submitted to surgery on the lower extremity or back as well as stroke patients. (Gray, 1985, Bates and McCaw, 1986; Kramer and Reid, 1981; Bates, Morrison, Hamill, 1984). Anecdotal reports of reduced noxious stress and beneficial proprioceptive stimulation have perpetuated the use of this form of physical therapy. Position specific sport training necessitates backward locomotion to engender efficient game performances. In numerous sport activities the defensive techniques employed entail retreating or "jockeying" maneuvers. Evasive offensive techniques likewise include backward travel. Some coaches and athletes are supplementing their conventional fitness training regimens with backwards running claiming enhanced hip extensor overloading with the resulting strength adaptation (Morton, 1985)

Improving the Patient Colonoscopy Prep Experience

AIM: To improve patient prep compliance, prep quality, and an overall better experience by designing a prep specific website that will address the most common prep questions and concerns Once launched, the website address will be placed on printed colonoscopy prep instructions and stated on the after hours GI clinic voicemail as an additional patient resourcehttps://jdc.jefferson.edu/patientsafetyposters/1049/thumbnail.jp

The usefulness of growth hormone treatment for psychological status in young adult survivors of childhood leukaemia: an open-label study

-1 SD) were included in the study. A final group of 13 patients (9 males and 4 females), mean age 23.7 ± 2.9 years (range 20 – 29.7) completed a 2-year treatment with GH. IQ and neuropsychological performance were assessed at pre-treatment (T1) and after one (T2) and two (T3) years. ANOVA was performed with assessment at T1, T2 and T3 as repeated measurements factor. Relations between test score changes and changes of IGF-I levels were determined by calculating the Pearson correlation coefficient. Results Scores on the cognitive tests were in the normal range. Verbal short- and long-term memory performance decreased between T1 and T2, and increased between T2 and T3. Performance at T3 was not significantly different from that at T1. Performance for sustained attention improved from T1 to T2 and from T1 to T3. Visual-spatial memory was improved after one year of GH treatment. A significant positive correlation was found for Δ IGF-I (T2-T1) with difference scores of visual-spatial memory (T2-T1 and T3-T1), indicating that IGF-I increase after one year of GH treatment is associated with increase in cognitive-perceptual performance at month 12 and 24. Conclusion Since the level of intellectual functioning of our patient cohort was in the normal range the present finding that GH treatment has negative effects on verbal memory and positive on attention and visual-spatial memory warrants similar studies in other groups of ALL survivors. Also, a lower dose of GH should be determined inducing as much IGF as needed to improve verbal as well as visual cognitive functions. The present findings indicate that more knowledge is needed before GH treatment may be recommended to enhance cognitive functions in ALL survivors

The Use of Infliximab in Older Inflammatory Bowel Disease Patients

Limited data suggest anti-tumor necrosis factor (TNF) antibodies have equal efficacy but higher morbidity and mortality in older compared to younger inflammatory bowel disease (IBD) patients(1)

Efficacy and Safety of Infliximab in Older Inflammatory Bowel Disease Patients

Background: The limited data regarding treatment of inflammatory bowel disease (IBD) with anti-tumor necrosis factor antibodies in older patients suggest equal efficacy but higher morbidity and mortality compared to younger patients. This retrospective case control study aims to clarify the efficacy and safety of infliximab (IFX) in older IBD patients